Heart Failure Deep Dive SeriesEp 4 of 4
Managing Acute Heart Failure And Cardiogenic Shock

Hosted by Sarah Mitchell & James Carter

0:000:00

More from: Heart Failure Deep Dive Series

How Four Drugs Beat Heart Failure
CardiologyEP 1 OF 4
How Four Drugs Beat Heart Failure

Sarah Mitchell & James Carter

Diabetes Drugs For Stiff Heart Failure
CardiologyEP 2 OF 4
Diabetes Drugs For Stiff Heart Failure

Sarah Mitchell & James Carter

Semaglutide For Obese Heart Failure Patients
CardiologyEP 3 OF 4
Semaglutide For Obese Heart Failure Patients

Sarah Mitchell & James Carter

Key Takeaways
  • High-dose IV diuretics targeting full decongestion (NTproBNP trending down, less than 1000 pg/mL at discharge) reduces readmission
  • STRONG-HF: rapid GDMT initiation during/after ADHF with early close follow-up reduces 180-day death and readmission
  • DanGer Shock 2024: early Impella in MI cardiogenic shock improves 180-day survival; timing is critical - early beats late escalation
  • CardioMEMS remote PA pressure monitoring reduces HF hospitalisation by 37% in NYHA Class III (CHAMPION)
Save as PDF

Reviewed & published by
Cite This Article

Team TLSFE. Managing acute heart failure and cardiogenic shock. The Life Science Feed. Published June 1, 2026. Updated June 1, 2026. Accessed June 1, 2026. https://thelifesciencefeed.com/cardiology/heart-failure/practice/managing-acute-heart-failure-and-cardiogenic-shock.

Licence & Rights

© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.

Podcast Disclaimer
Editorial & AI Standards

All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.

Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.

References

[1] Felker GM et al. DOSE. N Engl J Med. 2011;364:797-805

[2] Mebazaa A et al. STRONG-HF. Lancet. 2022;400:1938-1952

[3] Thiele H et al. IABP-SHOCK II. N Engl J Med. 2012;367:1287-1296

[4] Moller JE et al. DanGer Shock. N Engl J Med. 2024;390:1304-1315

[5] Abraham WT et al. CHAMPION. Lancet. 2011;377:658-666